Ticker Details
Atossa Therapeutics, Inc. Atossa Genetics Inc mainly focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions.
IPO Date:	November 8, 2012
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$39.01M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.09 | 4.37%
Avg Daily Range (30 D):	$0.18 | 4.54%
Avg Daily Range (90 D):	$0.08 | 3.53%

Institutional Daily Volume
Avg Daily Volume:	.17M
Avg Daily Volume (30 D):	.48M
Avg Daily Volume (90 D):	.26M

Trade Size
Avg Trade Size (Sh.):	35
Avg Trade Size (Sh.) (30 D):	220
Avg Trade Size (Sh.) (90 D):	106

Institutional Trades
Total Institutional Trades:	168
Avg Institutional Trade:	$2.14M
Avg Institutional Trade (30 D):	$3.98M
Avg Institutional Trade (90 D):	$3.98M
Avg Institutional Trade Volume:	.04M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$5.33M
Avg Closing Trade (30 D):	$9.36M
Avg Closing Trade (90 D):	$9.36M
Avg Closing Volume:	106.53K

News

Aug 28, 2025 @ 12:30 PM Atossa Therapeutics CEO to Discuss Clinical Progre... Source: Prnewswire

Oct 14, 2024 @ 9:08 PM Atossa Therapeutics to Present at the 2024 Maxim H... Source: N/A

Jun 28, 2024 @ 12:30 PM Atossa Therapeutics Announces Updated Protocol for... Source: Atossa Therapeutics, Inc.

Jun 25, 2024 @ 1:40 PM Are Medical Stocks Lagging Alvotech (ALVO) This Y... Source: Zacks Equity Research

Jun 17, 2024 @ 12:30 PM Atossa Set to Join Russell 3000® Index Effectiv... Source: Atossa Therapeutics, Inc.

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS	$-.24	$-.07	$-.07
Diluted EPS	$-.24	$-.07	$-.07
Revenue	$M	$M	$M
Gross Profit
Net Income / Loss	$-30.18M	$-8.69M	$-8.42M
Operating Income / Loss	$-32.86M	$-9.25M	$-9.04M
Cost of Revenue
Net Cash Flow	$-3.68M	$M	$M
PE Ratio

Splits
Feb 02, 2026	1:15
Apr 20, 2018	1:12
Aug 26, 2016	1:15